Skip to main content
SpringerLink
Log in

Chronic Transfusion Support

  • Chapter
Book cover Red Cell Transfusion

Part of the book series: Contemporary Hematology ((CH))

  • 119 Accesses

Abstract

The purpose of this chapter is to describe the underlying principles of chronic red cell transfusion therapy and its complications. In addition, specific diseases are addressed in which a chronic transfusion protocol may be a reasonable option; current recommendations and potential alternatives to transfusion are also considered for patients affected by these diseases. With the development of new therapies, some diseases that previously required chronic transfusion support are no longer initially treated with transfusions. Although many diseases are addressed specifically, this discussion is not intended to be comprehensive. The featured diseases were chosen as representative examples; many of the diseases not specifically addressed bear similarities to those that are included.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Torrance J, Jacobs P, Restrepo A, et al. Intraerythrocytic adaptation to anemia. N Engl J Med 1970;283:165–169.

    Article  PubMed  CAS  Google Scholar 

  2. Roy SB, Bhatia ML, Mathur VS, Virmani S. Hemodynamic effects of chronic severe anemia. Circulation 1963;28:346–356.

    Article  PubMed  CAS  Google Scholar 

  3. Sproule BJ, Mitchell JH, Miller WF. Cardiopulmonary physiological responses to heavy exercise in patients with anemia. J Clin Invest 1960;39:378–388.

    Article  PubMed  CAS  Google Scholar 

  4. Russell MO, Goldberg HI, Hodson A, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood 1984;63:162–169.

    PubMed  CAS  Google Scholar 

  5. Emond AM, Collis R, Darvill D, et al. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr 1985;107:201–206.

    Article  PubMed  CAS  Google Scholar 

  6. Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood 1993;81:1109–1123.

    PubMed  CAS  Google Scholar 

  7. Mallouh AA, Asha M. Beneficial effect of blood transfusion in children with sickle cell chest syndrome. AJDC 1988;142:178–182.

    PubMed  CAS  Google Scholar 

  8. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med 1995;333:206–213.

    Article  PubMed  CAS  Google Scholar 

  9. Charache S, Conley CL. Rate of sickling of red cells during deoxygenation of blood from persons with various sickling disorders. Blood 1964;24:25–48.

    PubMed  CAS  Google Scholar 

  10. Schmalzer EA, Lee JO, Brown AK, et al. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels: implications for transfusion. Transfusion 1987;27:228–233.

    Article  PubMed  CAS  Google Scholar 

  11. Jan K, Usami S, Smith JA. Effects of transfusion on rheological properties of blood in sickle cell anemia. Transfusion 1982;22:17–20.

    Article  PubMed  CAS  Google Scholar 

  12. Rund D, Rachmilewitz E. Thalassemia major 1995: older patients, newer therapies. Blood Rev 1995;9:25–32.

    Article  PubMed  CAS  Google Scholar 

  13. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous B-thalassemia. N Engl J Med 1994;331:574–578.

    Article  PubMed  CAS  Google Scholar 

  14. Collins AF, Goncalves-Dias C, Haddad S, et al. Comparison of a transfusion preparation of newly formed red cells and standard washed red cell transfusions in patients with homozygous B-thalassemia. Transfusion 1994;34:517–520.

    Article  PubMed  CAS  Google Scholar 

  15. Greenberg PL. Treatment of myelodysplastic syndromes. Blood Rev 1991;5:42–50.

    Article  PubMed  CAS  Google Scholar 

  16. Bowen D, Culligan D, Jacobs A. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 1991;77:419–423.

    Article  PubMed  CAS  Google Scholar 

  17. Mittelman M. Recombinant erythropoietin in myelodysplastic syndromes: Whom to treat and how? More questions than answers. Acta Haematol 1993;90:53–57.

    Article  PubMed  CAS  Google Scholar 

  18. Mittelman M, Lessin LS. Clinical Application of recombinant erythropoietin in myelodysplasia. In: Spivak J, eds. Erythropoietin: Basic and Clinical Aspects. Hematology/Oncology Clinics of North America. Philadelphia: Saunders, 1994, pp. 993–1009.

    Google Scholar 

  19. Lichtman MA, Rowe JM. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 1982;60:279–283.

    PubMed  CAS  Google Scholar 

  20. Harris AL. Leukostasis associated with blood transfusion in acute myeloid leukemia. Br Med J 1978;1:1169–1171.

    Article  PubMed  CAS  Google Scholar 

  21. Young NS. Aplastic anemia. Lancet 1995;346:228–232.

    Article  PubMed  CAS  Google Scholar 

  22. Yomtovian R, Prince GM, Medof ME. The molecular basis for paroxysmal nocturnal hemoglobinuria. Transfusion 1993;33:852–873.

    Article  PubMed  CAS  Google Scholar 

  23. Rotoli B, Bessler M, Alfinito F, del Vecchio L. Membrane proteins in paroxysmal nocturnal haemoglobinuria. Blood Rev 1993;7:75–86.

    Article  PubMed  CAS  Google Scholar 

  24. Dacie JV. Transfusion of saline-washed red cells in nocturnal haemoglobinuria. Clin Sci 1948;7:65–75.

    PubMed  CAS  Google Scholar 

  25. Brecher ME, Taswell HF. Paroxysmal nocturnal hemoglobinuria and the transfusion of washed red cells: a myth revisited. Transfusion 1989;29:681–685.

    Article  PubMed  CAS  Google Scholar 

  26. Sirchia G, Ferrone S, Mercuriali F. Leukocyte antigen-antibody reaction and lysis of paroxysmal nocturnal hemoglobinuria erythrocytes. Blood 1970;36:334–336.

    PubMed  CAS  Google Scholar 

  27. Rosse WF. Transfusion in paroxysmal nocturnal hemoglobinuria: to wash or not to wash? Transfusion 1989;29:663–664.

    Article  PubMed  CAS  Google Scholar 

  28. Sirchia G, Zanella A. Transfusion of PNH patients. Transfusion 1990;30:479.

    Article  PubMed  CAS  Google Scholar 

  29. Beguin Y, Clemons GK, Oris R, Fillet G. Circulating erythropoietin levels after bone marrow transplantation: Inappropriate response to anemia in allogeneic transplants. Blood 1991;77:868–873.

    PubMed  CAS  Google Scholar 

  30. Ireland RM, Atkinson K, Concannon A, et al. Serum erythropoietin changes in auto-logous and allogeneic bone marrow transplant patients. Br J Haematol 1990;76:128–134.

    Article  PubMed  CAS  Google Scholar 

  31. Steegman JL, Lopez J, Otero MJ, et al. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. Bone Marrow Transplant 1992;10:541–546.

    Google Scholar 

  32. Klaesson S, Ringden O, Ljungman P, et al. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 1994;13:397–402.

    PubMed  CAS  Google Scholar 

  33. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639–1647.

    PubMed  Google Scholar 

  34. Hochberg MC, Arnold CM, Hogans BB, Spivak JL. Serum immunoreactive erythropoietin in rheumatoid arthritis: impaired response to anemia. Arthritis Rheum 1988;31:1318–1321.

    Article  PubMed  CAS  Google Scholar 

  35. Pincus T, Olsen JN, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990;89:161–168.

    Article  PubMed  CAS  Google Scholar 

  36. Mercuriali F, Gualtieri G, Sinigaglia L, et al. Use of recombinant human erythropoietin to assist autologous blood donation by anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Transfusion 1994;34:501–506.

    Article  PubMed  CAS  Google Scholar 

  37. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689–1692.

    Article  PubMed  CAS  Google Scholar 

  38. Case DC, Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85:801–806.

    Article  PubMed  Google Scholar 

  39. Spivak JL, Bender BS, Quinn TC. Hematologic abnormalities in the acquired immune deficiency syndrome. Am J Med 1984;77:224–228.

    Article  PubMed  CAS  Google Scholar 

  40. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192–197.

    Article  PubMed  CAS  Google Scholar 

  41. Jacobson MA, Peiperl L, Volberding PA, et al. Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome. Transfusion 1990;30:133–137.

    Article  PubMed  CAS  Google Scholar 

  42. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990;322:1488–1493.

    Article  PubMed  CAS  Google Scholar 

  43. Sloand E, Kumar P, Klein HG, et al. Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion 1994;34:48–53.

    Article  PubMed  CAS  Google Scholar 

  44. Busch MP, Lee T-H, Heitman J. Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected patients. Blood 1992;80:2128–2135.

    PubMed  CAS  Google Scholar 

  45. Brown KE, Young NS. Parvovirus B19 infection and hematopoiesis. Blood Rev 1995;9:176–182.

    Article  PubMed  CAS  Google Scholar 

  46. Luban NLC. Human parvoviruses: implications for transfusion medicine. Transfusion 1994;34:821–827.

    Article  PubMed  CAS  Google Scholar 

  47. Esbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med 1989;111:992–1000.

    Google Scholar 

  48. De Marchi S, Cecchin E, Villalta D, et al. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 1992;326:969–974.

    Article  PubMed  Google Scholar 

  49. Watson AJ, Gimenez LF, Cotton S, et al. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 1990;89:432–435.

    Article  PubMed  CAS  Google Scholar 

  50. The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991;18:50–59.

    Google Scholar 

  51. Kleinman KS, Schweitzer SU, Perdue ST, et al. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis 1989;14:486–495.

    PubMed  CAS  Google Scholar 

  52. Brubaker DB. Transfusion-associated graft-versus-host disease. In: Anderson KC, Ness PM (ed). Scientific Basis of Transfusion Medicine: Implications for Clinical Practice, Philadelphia: Saunders, 1994, p. 544.

    Google Scholar 

  53. McMilin KD, Johnson RL. HLA homozygosity and the risk of related-donor transfusion-associated graft-versus-host disease. Transfus Med Rev 1993;7:37–41.

    Article  PubMed  CAS  Google Scholar 

  54. Petz LD, Calhoun L, Yam P, et al. Transfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion 1993,33:742–750.

    Article  PubMed  CAS  Google Scholar 

  55. Foster GR, Carman WF, Thomas HC. Replication of hepatitis B and delta viruses: appearance of viral mutants. Semin Liver Dis 1991;11:121–127.

    Article  PubMed  CAS  Google Scholar 

  56. Dodd RY. The risk of transfusion-transmitted infection. N Engl J Med 1992;327:419–421.

    Article  PubMed  CAS  Google Scholar 

  57. Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369–373.

    Article  PubMed  CAS  Google Scholar 

  58. Nelson KE, Ahmed F, Ness PM, et al. Comparison of first and second generation ELISA screening tests in detecting HCV infections in transfused cardiac surgery patients. In: Program and Abstracts of the International Symposium on Viral Hepatitis and Liver Disease, Tokyo, Japan, May 1014, 1993, p. 50.

    Google Scholar 

  59. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721–1725.

    Article  PubMed  CAS  Google Scholar 

  60. Cox JV, Steane E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988;148:2485–2489.

    Article  PubMed  CAS  Google Scholar 

  61. Davies SC, Mc William AC, Hewitt PE, et al. Red cell alloimmunization in sickle cell disease. Br J Haematol 1986;63:241–245.

    Article  PubMed  CAS  Google Scholar 

  62. Orlina AR, Unger PJ, Koshy M. Post-transfusion alloimmunization in patients with sickle cell disease. Am J Hematol 1978;5:101–106.

    Article  PubMed  CAS  Google Scholar 

  63. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and allomimmunization in sickle cell disease. Blood 1990;76:1431–1437.

    PubMed  CAS  Google Scholar 

  64. Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990;322:1617–1621.

    Article  PubMed  CAS  Google Scholar 

  65. Rebulla P, Modell B. Transfusion requirements and effects in patients with thalas-semia major. Lancet 1991;337:277–280.

    Article  PubMed  CAS  Google Scholar 

  66. Diamond WJ, Brown FL, Bitterman P, et al. Delayed hemolytic transfusion reaction presenting as sickle-cell crisis. Ann Intern Med 1980;93:231–234.

    PubMed  CAS  Google Scholar 

  67. Milner PF, Squires JE, Larison PJ, et al. Posttransfusion crises in sickle cell anemia: role of delayed hemolytic reactions to transfusion. S Med J 1985;78:1462–1469.

    Article  CAS  Google Scholar 

  68. Ambruso DR, Githens JH, Alcorn R, et al. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987;27:94–98.

    Article  PubMed  CAS  Google Scholar 

  69. Tahhan HR, Holbrook CT, Braddy LR, et al. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion 1994;34:562–569.

    Article  PubMed  CAS  Google Scholar 

  70. Tahhan HR, Werner AL, Bergante RA, et al. Antigen-matching in the transfusional management of pediatric patients with sickle cell disease (abstract). Transfusion 1995;35:16S.

    Google Scholar 

  71. Ness PM. To match or not to match: the question for chronically transfused patients with sickle cell anemia. Transfusion 1994;34:558–560.

    Article  PubMed  CAS  Google Scholar 

  72. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567–573.

    Article  PubMed  CAS  Google Scholar 

  73. Cohen A, Schwartz E. Excretion of iron in response to deferoxamine in sickle cell anemia. J Pediatr 1978;92:659–662.

    Article  PubMed  CAS  Google Scholar 

  74. Kim HC, Dugan NP, Silber JH, et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 1994;83:1136–1142.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Karen E. King
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul M. Ness
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. New York Blood Center, NY, USA

    Marion E. Reid PhD

  2. American Red Cross Blood Services, Philadelphia, PA, USA

    Sandra J. Nance MS, MT(ASCP)SBB

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

King, K.E., Ness, P.M. (1998). Chronic Transfusion Support. In: Reid, M.E., Nance, S.J. (eds) Red Cell Transfusion. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4612-1798-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-1798-5_12

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4612-7288-5

  • Online ISBN: 978-1-4612-1798-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation